Patient considerations in the management of ulcerative colitis – role of vedolizumab

Abstract

Ulcerative colitis (UC) is a subtype of inflammatory bowel disease which causes inflammation of the large intestine and affects approximately 7.6–24.6 per 100,000 persons. The therapeutic goal for UC patients is inducing remission, maintaining remission, and ideally, obtaining mucosal healing. Vedolizumab, approved by the US Food and Drug Administration in May 2014 for the treatment of moderate-to-severe UC and Crohn’s disease, is a newly developed anti-integrin therapy. This review focuses on the preclinical development of vedolizumab and data from early trials, and details the results of the landmark trails that led to its approval in the USA with a specific focus on the management of UC. Additionally, data on safety and the current UC management protocols are also discussed.

Video abstract

Point your SmartPhone at the code above. If you have a QR code reader the video abstract will appear. Or use:

http://youtu.be/UtFlq6k0NDg

Keywords:

• inflammation
• mucosal healing
• remission
• immunomodulator drugs
• infliximab
• ulcerative colitis

Disclosure

Arun Swaminath is in the advisory board of Janssen and Abbvie. Megha Kothari and Prashant Mudireddy report no conflicts of interest in this work.